TSLP induces neutrophil mediated killing of methicillin-resistant staphylococcus aureus

US10201591B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• The Board of Trustees of the Leland Stanford Junior University · US

Inventors

• Warren J. Leonard · Bethesda, US
• Erin Elizabeth West · Washington Grove, US
• Rosanne Spolski · Silver Spring, US
• K. Christopher Garcia · Menlo Park, US

Key dates

• Filing date: Nov 7, 2016
• Grant date: Feb 12, 2019
• Expiry date: Nov 7, 2036

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K9/0019
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides a method of promoting the host defense of a patient to a bacterial infection comprising administering to a patient suffering or at risk of a bacterial infection, a pharmaceutical composition comprising an effective amount of the pleiotropic cytokine, thymic stromal lymphopoietin (TSLP) protein or polypeptide in an amount and at a location sufficient to promote the host defense of the patient to the bacterial infection. In a preferred embodiment, the bacterial infection is the infection of the patient with MRSA.The invention also provides a method of treating blood product, which comprises introducing a TSLP protein or polypeptide into such blood product, wherein the blood product is extracorporeal and comprises at least one neutrophil.